Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

Vaccine

Volumn 26, Issue 22, 2008, Pages 2788-2795

  Jaoko, Walter ^a   Nakwagala, Frederick N ^b   Anzala, Omu ^a   Manyonyi, Gloria Omosa ^a   Birungi, Josephine ^b   Nanvubya, Annet ^b   Bashir, Farah ^a   Bhatt, Kirana ^a   Ogutu, Hilda ^a   Wakasiaka, Sabina ^a   Matu, Lucy ^a   Waruingi, Wambui ^a   Odada, Jane ^a   Oyaro, Micah ^a   Indangasi, Jackton ^a   Ndinya Achola, Jeckonia ^a   Konde, Carol ^b   Mugisha, Emmanuel ^b   Fast, Patricia ^c   Schmidt, Claudia ^c   Gilmour, Jill ^d   Tarragona, Tony ^d   Smith, Carol ^e   Barin, Burc ^e   Dally, Len ^e   Johnson, Bruce ^c   Muluubya, Andrew ^b   Nielsen, Leslie ^c   Hayes, Peter ^d   Boaz, Mark ^d   Hughes, Peter ^b   Hanke, Tomáš ^f   McMichael, Andrew ^f   Bwayo, Job ^a   Kaleebu, Pontiano ^b   more..

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e EMMES CORPORATION   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

DNA vaccine; East Africa; HIV AIDS vaccine; Phase 1 clinical trials; Recombinant MVA vaccine

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; PLASMID DNA; PLASMID VECTOR; VIRUS VECTOR;

ADULT; AFRICA; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; KENYA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISCOLORATION; SKIN INDURATION; TINNITUS; UGANDA; VACCINIA VIRUS;

ADULT; AIDS VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV-1; HUMANS; INTERFERON TYPE II; KENYA; LEUKOCYTES, MONONUCLEAR; MALE; PLACEBOS; PLASMIDS; UGANDA; VACCINES, DNA; VACCINIA VIRUS;

EID: 43049181912     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.071     Document Type: Article

References (27)

1. Hanke T., and McMichael A. Design and construction of an experimental HIV-I vaccine for a year-2000 clinical trial in Kenya. Nat Med 6 9 (2000) 951-955
2. Dorrell L., Dong T., Ogg G.S., Lister S., McAdam S., Rostron T., et al. Distinct recognition of clade A HIV-1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol 73 2 (1999) 1708-1714
3. Takahashi H., Houghten R., Putney S.D., Margulies D.H., Moss B., Germain R.N., et al. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of immunodominant determinant of the human immunodeficiency virus envelope protein. J Exp Med 170 (1989) 2023-2035
4. Allen T.M., Sidney J., del Guercio M.F., Glickman R.L., Lensmeyer G.L., Wiebe D.A., et al. Characterization of the peptide-binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from SIV. J Immunol 160 (1998) 6062-6071
5. Hanke T., McMichael A.J., Samuel R.V., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21 (2002) 108-114
6. Hanke T., Blanchard T.J., Schneider J., et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 79 Pt 1 (1998) 83-90
7. Wee E.G., Patel S., McMichael A.J., and Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in Rhesus Macaques. J Gen Virol 83 Pt 1 (2002) 75-80
8. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
9. Hanke T., McMichael A.J., and Dorell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88 (2007) 1-12
10. Lihana R.W., Khamadi S.A., Kiptoo M.K., Kinyua J.G., Lagat N., Magoma G.N., et al. HIV type 1 subtypes among STI patients in Nairobi: a genotypic study based on partial pol gene sequencing. AIDS Res Hum Retroviruses 22 11 (2006) 1172-1177
11. Mugerwa R.D., Kaleebu P., Mugyenyi P., Katongole-Mbidde E., Hom D.L., Byaruhanga R., et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ 324 7331 (2002) 226-229
12. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multi-functional HIV-1-specific T cells capable of proliferation in healthy subjects by a prime-boost regimen of DNA- and MVA-vectored vaccines expressing HIV-1 gag coupled to CD8+ T cell epitopes. J Virol 80 10 (2006) 4717-4728
13. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25 (2007) 2120-2127
14. ® challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine 25 (2007) 1513-1525
15. Robertson J.S., and Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Mol Biotechnol 17 (2001) 143-149
16. Giri M., Ugen K.E., and Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 17 2 (2004) 370-389
17. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 91 2 (2006) 610-619
18. Haynes J.R., Fuller D.H., McCabe D., Swain W.F., and Widera G. Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Deliv Rev 21 (1996) 3-18
19. Sedegah M., Weiss W., Sacci Jr. J.B., Charoenvit Y., Hedstrom R., Gowda K., et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressed recombinant poxvirus. J Immunol 164 11 (2000) 5905-5912
20. Kim J.J., Yang J.S., VanCott T.C., Lee D.J., Manson K.H., Wyand M.S., et al. Modulation of antigen-specific humoral responses in Rhesus Macaques by using cytokine cDNAs as DNA vaccine adjuvants. J Virol 74 7 (2000) 3427-3429
21. Calarota S.A., and Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 199 (2004) 84-99
22. Heller L.C., Ugen K., and Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2 (2005) 255-268
23. Dean H.J. Epidermal delivery of protein and DNA vaccines. Expert Opin Drug Deliv 2 (2005) 227-236
24. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trial: stimulation of HIV-1 specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85 Pt 4 (2004) 911-919
25. Dorrell L., Yang H., Ondondo B., et al. Quantitative and qualitative changes in virus-specific CD8+ T cell responses in HIV-1-infected individuals on antiretroviral therapy induced by vaccination with recombinant modified virus Ankara (MVA) expressing HIV-1 gag. J Virol 80 (2006) 4705-4716
26. Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B' MVA-based HIV-1 Candidate Vaccine, in healthy volunteers: presentation at AIDS Vaccine 2007. Seattle, Washington, USA; August 20-23, 2007.
27. Study to Evaluate the Safety and Immunogenicity of a Recombinant Modified Vaccinia: Ankara Virus (TBC-M4) multigenic HIV subtype C Vaccine. AIDS Vaccine 2007. Seattle, Washington, USA; August 20-23, 2007 [abstract P06-02].